Purpose: Little is known about other primary neoplasms occurring in patients with hepatocellular cancer (HCC). This team attempted to characterize this cohort of patients to define incidence, risk factors, natural history, and potentially shared etiologies.
Methods: A retrospective analysis from an established, prospective database of patients with HCC during 1991-2004 was used to determine demographic data, risk factors, characteristics of the associated second primary neoplasm, and survival.
Main Findings: Of 306 patients with HCC, 23 patients (7.5%) were identified with a second neoplasm. Two of these patients had a third neoplasm. Mean age was 65.6 years and male:female ratio was 2.3:1. Risk factors included: hepatitis B (27.3%), hepatitis C (40.9%), smoking (17.4 %), diabetes (26.1%), cirrhosis (63.6%), and family history of HCC (4.5%). Second associated primaries included 7 genitourinary (prostate--2, bladder--2, testicular--1, renal--1, ovarian--1), 7 gastrointestinal (colon--6, gastric--1), 3 breast, 2 skin, 2 lung, 2 hematologic, 1 tongue, and 1 desmoid. Four patients had HCC first, 1 patient had synchronous HCC and colon cancer, while 18 had the other primary first. Mean, 1 and 2-year survival after diagnosis of HCC was 1014.8 days, 75%, and 30%, compared to 782.6 days, 54.6%, and 41.1%, respectively, in the group with HCC only (p > 0.05).
Conclusion: The incidence of other primary tumors in the setting of HCC is relatively common with a strong clustering of genitourinary and gastrointestinal malignancies. There was no statistically significant difference in overall survival compared to patients with HCC only, suggesting that the association of other primary tumors with HCC does not confer a worse prognosis.
Download full-text PDF |
Source |
---|
BMJ Case Rep
January 2025
General Surgery, Hospital Universitario HM Sanchinarro, Madrid, Spain
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare variant of hepatocellular carcinoma (HCC), characterised by a poorer prognosis in later stages compared with conventional HCC due to a high rate of local recurrence, lymph node metastasis and peritoneal metastasis. Conventional chemotherapy is generally ineffective, making surgery the only potentially curative treatment. Currently, surgery is also indicated in cases of recurrence, always aiming for an R0 resection.
View Article and Find Full Text PDFHPB (Oxford)
December 2024
Department of Surgery, Division of Surgical Oncology, The Ohio State University, Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Background: Genomic variations related to racial and sex differences among patients with hepatocellular carcinoma (HCC) have not been investigated. We sought to characterize the mutational landscape of patients with HCC relative to race and sex.
Methods: The American Association for Cancer Research GENIE project (v16.
Adv Med Sci
January 2025
Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, P.R. China. Electronic address:
Purpose: This study aims to evaluate the prognostic value of contrast-enhanced ultrasound (CEUS) combined with tumour markers in patients with hepatocellular carcinoma (HCC) undergoing microwave ablation (MWA).
Methods: MWA patients with HCC were divided into good prognosis (n = 75) and poor prognosis (n = 69) groups. The levels of alpha-fetoprotein (AFP), carbohydrate antigen (CA19-9), and carcinoembryonic antigen (CEA) before and after MWA were analysed using an independent sample t-test.
Cancer Control
January 2025
Department of Pharmacy, Wuhan Third Hospital, Wuhan, China.
Objective: This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.
Methods: 216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated.
Advances in imaging techniques have evolved, allowing for early noninvasive diagnosis and improved management of high-risk patients with hepatocellular carcinoma (HCC). The hallmark imaging features of HCC on multiphasic cross-sectional imaging can be explained by the multistep process of hepatocarcinogenesis and is seen in 60% of cases. However, approximately 40% of cases do not abide by the classic imaging appearance and may pose a diagnostic challenge for radiologists.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!